Skip to main content

Table 1 Univariate and multivariate analysis of 3-DFS in stage II dMMR patients

From: The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study

Variables

N (%)

Univariate Analysis

Multivariate Analysis

HR (95% CI)

P-value

HR (95% CI)

P-value

Age (years)

 ≥ 65

53(20.2)

1.16(0.43–3.15)

0.769

  

 < 65

209(79.8)

    

Gender

 Male

162(61.8)

1.35(0.55–3.32)

0.508

  

 Female

100(38.2)

    

Family history

 Yes

110(42.0)

1.14(0.49–2.64)

0.762

  

 No

152(58.0)

    

pT4 category

 Yes

46(17.6)

2.93(1.23–6.98)

0.015

2.58(1.06–6.25)

0.037

 No

216(82.4)

    

Lymphatic node number

 < 12 LNs

41(15.7)

2.16(0.85–5.53)

0.107

  

 ≥ 12 LNs

221(84.3)

    

LVI

 Yes

29(11.1)

2.54(0.94–6.89)

0.067

1.71(0.60–4.89)

0.316

 No

233(88.9)

    

PNI

 Yes

21(8.0)

1.18(0.28–5.04)

0.830

  

 No

241(92.0)

    

Histological grade

 Poorly differentiated

98(37.4)

2.08(0.90–4.82)

0.087

1.65(0.68–4.02)

0.270

 Moderately differentiated

164(62.6)

    

Pre-CEA

 Abnormal (> 5 ng/ml)

77(29.4)

3.08(1.33–7.12)

0.009

2.93(1.26–6.82)

0.013

 Normal

185(80.6)

    

High-risk Factor

 Yes

179(68.3)

3.08(0.91–10.41)

0.056

  

 No

83(31.7)

    

Multiple risk Factor

 Yes

91(34.7)

2.88(1.23–6.74)

0.015

  

 No

171(65.3)

    
  1. Abbreviations: < 12 LNs Fewer than twelve lymph nodes harvested, LVI Lymphatic vascular invasion, PNI Perineural invasion, Pre-CEA Preoperative carcinoembryonic antigen HR Hazard ratio